search
Back to results

Low-dose Dexamethasone in Newly Diagnosed Pulmonary Sarcoidosis (DEXSAR)

Primary Purpose

Sarcoidosis

Status
Unknown status
Phase
Phase 3
Locations
Netherlands
Study Type
Interventional
Intervention
Dexamethasone
Placebo
Sponsored by
St. Antonius Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Sarcoidosis

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Diagnosis of sarcoidosis, confirmed by histology or cytology
  • Age 18-60 years
  • No affected organ requiring high dose immunosuppressive therapy
  • Short Form - 36 subscale physical functioning score < 70 points

Exclusion Criteria:

  • Allergy to corticosteroids
  • Diagnosis of glaucoma, osteoporosis, history of fractures
  • History of gastric ulcera in the past 12 months
  • Current use of Non Steroidal Anti Inflammatory Drug without co-prescription of Proton Pump Inhibitor
  • Current use of carbamazepin, fenytoin, rifampicin
  • Obesity (BMI > 30)
  • Pregnancy of lactation

Sites / Locations

  • St Antonius HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Dexamethasone 1 mg

Placebo

Arm Description

Dexamethasone 1 mg per day, for 180 days

Placebo tablet, for 180 days

Outcomes

Primary Outcome Measures

Change in health-related quality of life versus baseline
The primary outcome measure is the change in health-related quality of life compared with baseline.

Secondary Outcome Measures

Full Information

First Posted
August 7, 2013
Last Updated
November 18, 2014
Sponsor
St. Antonius Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT01920919
Brief Title
Low-dose Dexamethasone in Newly Diagnosed Pulmonary Sarcoidosis
Acronym
DEXSAR
Study Type
Interventional

2. Study Status

Record Verification Date
November 2014
Overall Recruitment Status
Unknown status
Study Start Date
June 2013 (undefined)
Primary Completion Date
August 2016 (Anticipated)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
St. Antonius Hospital

4. Oversight

5. Study Description

Brief Summary
This trial examines whether low grade suppression of the initial inflammatory process of sarcoidosis by intervention with low-dose dexamethasone therapy achieves significant alleviation of (sub-)acute symptoms, improvement in quality of life, increase in work productivity, and whether this intervention prevents disease progression and reduces total health-care costs.
Detailed Description
The orphan disease sarcoidosis causes a major reduction in quality of life and loss of work productivity, especially in young adults. Most patients are diagnosed between the age of 20-40 years. In sarcoidosis, multiple organs are affected by inflammation; the cause of the disease is unknown and no curative medication exists. Sarcoidosis invalidates the lives of most patient for many years. Although curative (pharmaco) therapy is not on hand, immunosuppressive drugs may control the symptoms of the disease. These symptoms are caused by the inflammation in multiple organs, foremost the lungs and the lymphoid system. However, 90% of the sarcoidosis patients receives no immunosuppressive medication at all during the first months after diagnosis, even though the immune system is then highly activated and patients suffer from severe complaints like malaise, fatigue and pain. This wait-and-see policy is common international practice, but scientific grounds and official guidelines are lacking. This project examines whether low grade suppression of the initial inflammatory process of sarcoidosis by intervention with low-dose dexamethasone therapy achieves significant alleviation of (sub-)acute symptoms, improvement in quality of life, increase in work productivity, and whether this intervention prevents disease progression and reduces total health-care costs.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sarcoidosis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
76 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Dexamethasone 1 mg
Arm Type
Experimental
Arm Description
Dexamethasone 1 mg per day, for 180 days
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo tablet, for 180 days
Intervention Type
Drug
Intervention Name(s)
Dexamethasone
Intervention Type
Drug
Intervention Name(s)
Placebo
Primary Outcome Measure Information:
Title
Change in health-related quality of life versus baseline
Description
The primary outcome measure is the change in health-related quality of life compared with baseline.
Time Frame
0, 3, 6, 12, 18, 24 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Diagnosis of sarcoidosis, confirmed by histology or cytology Age 18-60 years No affected organ requiring high dose immunosuppressive therapy Short Form - 36 subscale physical functioning score < 70 points Exclusion Criteria: Allergy to corticosteroids Diagnosis of glaucoma, osteoporosis, history of fractures History of gastric ulcera in the past 12 months Current use of Non Steroidal Anti Inflammatory Drug without co-prescription of Proton Pump Inhibitor Current use of carbamazepin, fenytoin, rifampicin Obesity (BMI > 30) Pregnancy of lactation
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Roeland Vis
Phone
0031 30 609 2612
Email
r.vis@antoniusziekenhuis.nl
Facility Information:
Facility Name
St Antonius Hospital
City
Nieuwegein
ZIP/Postal Code
3430 EM
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Roeland Vis

12. IPD Sharing Statement

Learn more about this trial

Low-dose Dexamethasone in Newly Diagnosed Pulmonary Sarcoidosis

We'll reach out to this number within 24 hrs